Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The study was prematurely discontinued due to the substantial delay in initiation the study. This decision was not due to major safety concerns or requests from any regulatory authorities.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to collect information on the:
In adult patients with COVID-19 who have been prescribed nirmatrelvir and ritonavir treatment.
This study will be conducted in Morocco. The study will capture information of the adult COVID-19 outpatients and inpatients who have been prescribed nirmatrelvir, ritonavir treatment. The inpatients will be admitted in the hospital for other reasons than COVID-19.
This study will have about 150 patients. The study will involve collection of patient information from medical records. The information collected can be either from papers or from computers.
The study will include patient information of those who:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Participants receiving Paxlovid Treatment | Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Nirmatrelvir/Ritonavir | Drug | Patients administered oral Paxlovid as prescribed according to national Morocco treatment guidelines for Covid. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Demographical Characteristics of Participants | Approximately 01 June 2022 through 30 June 2023 | |
| Clinical Characteristics of Participants | Approximately 01 June 2022 through 30 June 2023 | |
| Number of Participants with Pre-existing Comorbidities | Approximately 01 June 2022 through 30 June 2023 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Participants treated with Paxlovid in single center in Morocco.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pfizer CT.gov Call Center | Pfizer | Study Director |
Not provided
Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical\_trials/trial\_data\_and\_results/data\_requests.
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000719967 | nirmatrelvir and ritonavir drug combination |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|